nach oben

Current Fungal Infection Reports

Erschienen in:

20.06.2020 | Fungal Infections in Transplantation (S Shoham, Section Editor)

Cryptococcosis in Liver Transplant Candidates and Recipients

verfasst von: Sara Gore, Graeme N. Forrest

Erschienen in: Current Fungal Infection Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Evaluate the epidemiology, risk factors, pathophysiology, and clinical outcomes of cryptococcal infections in patients with advanced liver disease or liver transplantation.

Recent Findings

Cryptococcal infections in patients with advanced liver disease (ALD) are uncommon but associated with high mortality. Less than 10% of patients in a prospective study of non-HIV-infected cryptococcal meningitis patients had ALD. Significantly, fever was uncommon, resulting in delays in diagnosis. Modalities for diagnosing cryptococcal infections include the rapid lateral flow cryptococcal antigen (CrAg) assay from serum and cerebrospinal fluid (CSF) specimens and multiplex polymerase chain reactions from CSF. Screening all ALD patients with CrAg has not been beneficial.

Summary

Cryptococcal infections in patients with ALD and liver transplantation result in poor outcomes due to diagnostic delays and concomitant impaired liver function with hepatotoxic therapies. A high index of suspicion is necessary as routine screening has very low yield for early detection.

Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: what do we know now. Fungal Genet Biol. 2015;78:49–54. https://doi.org/10.1016/j.fgb.2014.10.003.CrossRefPubMed

• Kwon-Chung KJ, Bennett JE, Wickes BL, Meyer W, Cuomo CA, Wollenburg KR, et al. The case for adopting the “species complex” nomenclature for the etiologic agents of Cryptococcosis. mSphere. 2017;2(1):e00357. https://doi.org/10.1128/mSphere.00357-16Explains the proposed cryptococcal species nomenclature changes. CrossRefPubMedPubMedCentral

Jin L, Cao JR, Xue XY, Wu H, Wang LF, Guo L, et al. Clinical and microbiological characteristics of Cryptococcus gattii isolated from 7 hospitals in China. BMC Microbiol. 2020;20(1):73. https://doi.org/10.1186/s12866-020-01752-4.CrossRefPubMedPubMedCentral

Steenbergen JN, Casadevall A. Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City. J Clin Microbiol. 2000;38(5):1974–6.CrossRef

Harris JR, Lockhart SR, DeBess E, Marsden-Haug N, Goldoft M, Wohrle R, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. ClinInfectDis. 2011;53(12):1188–95.

• Patel V, Desjardins M, Cowan J. Shift in epidemiology of cryptococcal infections in Ottawa with high mortality in non-HIV immunocompromised patients. J Fungi (Basel). 2019;5(4):104. https://doi.org/10.3390/jof5040104Shows how treating HIV has altered the epidemiology of cryptococcus towards more non-HIV patients. CrossRef

Singh N, Sifri CD, Silveira FP, Miller R, Gregg KS, Huprikar S, et al. Cryptococcosis in patients with cirrhosis of the liver and posttransplant outcomes. Transplantation. 2015;99(10):2132–41. https://doi.org/10.1097/TP.0000000000000690.CrossRefPubMed

Wajszczuk CP, Dummer JS, Ho M, Van Thiel DH, Starzl TE, Iwatsuki S, et al. Fungal infections in liver transplant recipients. Transplantation. 1985;40(4):347–53. https://doi.org/10.1097/00007890-198510000-00002.CrossRefPubMedPubMedCentral

Mabee CL, Mabee SW, Kirkpatrick RB, Koletar SL. Cirrhosis: a risk factor for cryptococcal peritonitis. Am J Gastroenterol. 1995;90(11):2042–5.PubMed

10.

• Spec A, Raval K, Powderly WG. End-stage liver disease is a strong predictor of early mortality in Cryptococcosis. Open Forum Infect Dis. 2016;3(1):ofv197. https://doi.org/10.1093/ofid/ofv197Important paper on the early high mortality associated with ALD. CrossRefPubMed

11.

•• Marr KA, Sun Y, Spec A, Lu N, Panackal A, Bennett J, et al. A multicenter, longitudinal cohort study of Cryptococcosis in human immunodeficiency virus-negative people in the United States. Clin Infect Dis. 2020;70(2):252–61. https://doi.org/10.1093/cid/ciz193Significant paper on clinical findings of non-HIV patients withCryptococcus. 10% had ALD. CrossRefPubMed

12.

Spies FS, de Oliveira MB, Krug MS, Severo CB, Severo LC, Vainstein MH. Cryptococcosis in patients living with hepatitis C and B viruses. Mycopathologia. 2015;179(3–4):307–12. https://doi.org/10.1007/s11046-014-9843-4.CrossRefPubMed

13.

Berinstein J, Likhitsup A, Vedula SC, Conjeevaram H. Cryptic but deadly: a serious killer in patients with advanced liver disease that should not be missed. Cureus. 2017;9(12):e1976. https://doi.org/10.7759/cureus.1976.CrossRefPubMedPubMedCentral

14.

Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore). 2004;83(3):188–92. https://doi.org/10.1097/01.md.0000126760.45299.69.CrossRef

15.

• Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLoS One. 2013;8(2):e56269. https://doi.org/10.1371/journal.pone.0056269Large pool of patients with cryptococcal meningitis based on ICD codes, with risks identified by subgroups. CrossRefPubMedPubMedCentral

16.

Suh HJ, Choe PG, Song KH, Park WB, Bang JH, Kim ES, et al. Prevalence of cryptococcal antigenemia in hospitalized patients with liver cirrhosis. Med Mycol. 2020;58(2):207–10. https://doi.org/10.1093/mmy/myz045.CrossRefPubMed

17.

Rohatgi S, Pirofski LA. Host immunity to Cryptococcus neoformans. Future Microbiol. 2015;10(4):565–81. https://doi.org/10.2217/fmb.14.132.CrossRefPubMedPubMedCentral

18.

Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2016;30(1):179–206. https://doi.org/10.1016/j.idc.2015.10.006.CrossRef

19.

• Pirofski LA, Casadevall A. The damage-response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases. J Infect Dis. 2018;218(suppl_1):S7–S11. https://doi.org/10.1093/infdis/jiy083This review helps explain the host response to cryptococcal infection. The response can be as dangerous as the fungal infection. CrossRefPubMedPubMedCentral

20.

Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis. 1998;4(1):71–83. https://doi.org/10.3201/eid0401.980109.CrossRefPubMedPubMedCentral

21.

Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol. 2013;190(8):3959–66. https://doi.org/10.4049/jimmunol.1202526.CrossRefPubMedPubMedCentral

22.

Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. ClinInfectDis. 2010;50(3):291–322.

23.

Jalali Z, Ng L, Singh N, Pirofski LA. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation. Clin Vaccine Immunol. 2006;13(7):740–6. https://doi.org/10.1128/CVI.00139-06.CrossRefPubMedPubMedCentral

24.

Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(9):727–38. https://doi.org/10.1016/j.cgh.2011.02.031.CrossRefPubMed

25.

Nouri-Aria KT, Alexander GJ, Portmann BC, Hegarty JE, Eddleston AL, Williams R. T and B cell function in alcoholic liver disease. J Hepatol. 1986;2(2):195–207. https://doi.org/10.1016/s0168-8278(86)80078-2.CrossRefPubMed

26.

Rohilla R, Meena S, Kaistha N, Krishna Raj A, Gupta P. Disseminated cryptococcosis and hepatitis C virus infection: a fatal co-infection. Curr Med Mycol. 2019;5(4):50–3. https://doi.org/10.18502/cmm.5.4.2163.CrossRefPubMedPubMedCentral

27.

Singh N, Sun HY. Iron overload and unique susceptibility of liver transplant recipients to disseminated disease due to opportunistic pathogens. Liver Transpl. 2008;14(9):1249–55. https://doi.org/10.1002/lt.21587.CrossRefPubMed

28.

Jung WH, Sham A, White R, Kronstad JW. Iron regulation of the major virulence factors in the AIDS-associated pathogen Cryptococcus neoformans. PLoS Biol. 2006;4(12):e410. https://doi.org/10.1371/journal.pbio.0040410.CrossRefPubMedPubMedCentral

29.

Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. 2005;129(2):494–503. https://doi.org/10.1016/j.gastro.2005.05.004.CrossRefPubMed

30.

Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl. 2006;12(12):1799–804. https://doi.org/10.1002/lt.20827.CrossRefPubMed

31.

Sena Corrales G, Perez Medina MI, Costo Muriel C, Reguera Iglesias JM. Cryptococcus neoformans peritonitis in the cirrhotic patient. Enferm Infecc Microbiol Clin. 2018;36(7):456–7. https://doi.org/10.1016/j.eimc.2017.10.011.CrossRefPubMed

32.

Flagg SD, Chang YJ, Masuell CP, Natarajan S, Hermann G, Mendelson MH. Myositis resulting from disseminated cryptococcosis in a patient with hepatitis C cirrhosis. Clin Infect Dis. 2001;32(7):1104–7. https://doi.org/10.1086/319589.CrossRefPubMed

33.

Singh DK, Tyagi I, Saran RK, Gondal R. Fatal spontaneous Cryptococcal peritonitis in a woman with decompensated liver cirrhosis. Acta Cytol. 2010;54(5 Suppl):1087–9.PubMed

34.

Paliwal VK, Gupta PK, Rai P, Verma R. Cryptococcal meningitis in a patient with hepatitis C virus related decompensated cirrhosis: coincidental or immunologically related? Trop Gastroenterol. 2012;33(2):146–8. https://doi.org/10.7869/tg.2012.34.CrossRefPubMed

35.

Hwang SY, Yu SJ, Lee JH, Kim JS, Yoon JW, Kim YJ, et al. Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol Infect Dis. 2014;33(2):259–64. https://doi.org/10.1007/s10096-013-1953-2.CrossRefPubMed

36.

Hoshiai S, Hiyama T, Kawasaki H, Saitoh H, Mori K, Nasu K, et al. Mass-forming hepatic cryptococcosis: a mimicker of metastatic tumors. Abdom Radiol (NY). 2020. https://doi.org/10.1007/s00261-020-02437-2.

37.

•• Barnett AE, Brust KB. Cirrhosis, gastrointestinal bleed, and cryptococcal peritonitis. Proc (Baylor Univ Med Cent). 2020;33(2):195–8. https://doi.org/10.1080/08998280.2020.1723361Case report and review of cryptococcal peritoneal infections. CrossRef

38.

Jean SS, Wang JL, Wang JT, Fang CT, Chen YC, Chang SC. Cryptococcus neoformans peritonitis in two patients with liver cirrhosis. J Formos Med Assoc. 2005;104(1):39–42.PubMed

39.

Saif MW, Raj M. Cryptococcal peritonitis complicating hepatic failure: case report and review of the literature. J Appl Res. 2006;6(1):43–50.PubMedPubMedCentral

40.

Bal CK, Bhatia V, Khillan V, Rathor N, Saini D, Daman R, et al. Spontaneous cryptococcal peritonitis with fungemia in patients with decompensated cirrhosis: report of two cases. Indian J Crit Care Med. 2014;18(8):536–9. https://doi.org/10.4103/0972-5229.138161.CrossRefPubMedPubMedCentral

41.

Wang J, Hong JJ, Zhang PP, Yang MF, Yang Q, Qu TT. Cryptococcal pleuritis with pleural effusion as the only clinical presentation in a patient with hepatic cirrhosis: a case report and literature review. Medicine (Baltimore). 2019;98(28):e16354. https://doi.org/10.1097/MD.0000000000016354.CrossRef

42.

Sabesin SM, Fallon HJ, Andriole VT. Hepatic failure as a manifestation of cryptococcosis. Arch Intern Med. 1963;111:661–9. https://doi.org/10.1001/archinte.1963.03620290127018.CrossRefPubMed

43.

Martin L, Drouhet E, Destombes P, Dziubinski K, Osetowska E. Anatomic and clinical study of a case of meningeal cryptococcosis (Cryptococcus neoformans), treated with amphotericin B, in a patient with liver cirrhosis. Neuropatol Pol. 1967;5(3):287–96.PubMed

44.

Clift SA, Bradsher RW, Chan CH. Peritonitis as an indicator of disseminated cryptococcal infection. Am J Gastroenterol. 1982;77(12):922–4.PubMed

45.

Daly JS, Porter KA, Chong FK, Robillard RJ. Disseminated, nonmeningeal gastrointestinal cryptococcal infection in an HIV-negative patient. Am J Gastroenterol. 1990;85(10):1421–4.PubMed

46.

Cleophas V, George V, Mathew M, Samal SC, Chandy GM. Spontaneous fungal peritonitis in patients with hepatitis B virus-related liver disease. J Clin Gastroenterol. 2000;31(1):77–9. https://doi.org/10.1097/00004836-200007000-00018.CrossRefPubMed

47.

Sungkanuparph S, Vibhagool A, Pracharktam R. Spontaneous cryptococcal peritonitis in cirrhotic patients. J Postgrad Med. 2002;48(3):201–2.PubMed

48.

Albert-Braun S, Venema F, Bausch J, Hunfeld KP, Schafer V. Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature. Infection. 2005;33(4):282–8. https://doi.org/10.1007/s15010-005-4120-6.CrossRefPubMed

49.

Chaudhary A, Aladag M, Rashwan S, Wright H, Nour B, Gurakar A. Disseminated Cryptococcus neoformans in a cirrhotic patient. J Okla State Med Assoc. 2005;98(4):145–6.PubMed

50.

Franca AV, Carneiro M, Dal Sasso K, da Souza CS, Martinelli A. Cryptococcosis in cirrhotic patients. Mycoses. 2005;48(1):68–72. https://doi.org/10.1111/j.1439-0507.2004.01064.x.CrossRefPubMed

51.

Chuang YM, Ho YC, Chang HT, Yu CJ, Yang PC, Hsueh PR. Disseminated cryptococcosis in HIV-uninfected patients. Eur J Clin Microbiol Infect Dis. 2008;27(4):307–10. https://doi.org/10.1007/s10096-007-0430-1.CrossRefPubMed

52.

Wang YC. Four-week fluconazole treatment is recommended for localized granulomatous cryptococcal prostatitis in patients with liver cirrhosis. Int J Urol. 2009;16(12):980–1; author reply 1. https://doi.org/10.1111/j.1442-2042.2009.02407.x.CrossRefPubMed

53.

Yehia BR, Eberlein M, Sisson SD, Hager DN. Disseminated cryptococcosis with meningitis, peritonitis, and cryptococcemia in a HIV-negative patient with cirrhosis: a case report. Cases J. 2009;2:170. https://doi.org/10.1186/1757-1626-2-170.CrossRefPubMedPubMedCentral

54.

Aruch DB, Bhusal Y, Hamill RJ. Unusual cause of cellulitis in a patient with hepatitis C and cirrhosis. Am J Med. 2011;124(7):e7–8. https://doi.org/10.1016/j.amjmed.2011.01.021.CrossRefPubMed

55.

El-Kersh K, Rawasia WF, Chaddha U, Guardiola J. Rarity revisited: cryptococcal peritonitis. BMJ Case Rep. 2013;2013:bcr2013009099. https://doi.org/10.1136/bcr-2013-009099.CrossRefPubMedPubMedCentral

56.

Choi HM, Jung GM, Lee WK, Lee HS, Kim BS, Seong CS, et al. A case of cryptococcal meningitis mimicking hepatic encephalopathy in a patient with liver cirrhosis caused by chronic hepatitis C. Korean J Gastroenterol. 2014;64(5):294–7. https://doi.org/10.4166/kjg.2014.64.5.294.CrossRefPubMed

57.

Kandula M, Kelkar AH, Liberio N, Aiyer MK. Cryptococcemia in an HIV-negative patient with decompensated liver cirrhosis. J Community Hosp Intern Med Perspect. 2016;6(6):33383. https://doi.org/10.3402/jchimp.v6.33383.CrossRefPubMed

58.

Koba S, Ueda K, Mori M, Miki K, Imashuku S. Fatal invasive cryptococcal infection in an HIV-negative elderly patient with decompensated hepatic cirrhosis. Case Reports Hepatol. 2018;2018:5174518–6. https://doi.org/10.1155/2018/5174518.CrossRefPubMedPubMedCentral

59.

Sifri CD, Sun HY, Cacciarelli TV, Wispelwey B, Pruett TL, Singh N. Pretransplant cryptococcosis and outcome after liver transplantation. Liver Transpl. 2010;16(4):499–502. https://doi.org/10.1002/lt.22024.CrossRefPubMed

60.

Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11. https://doi.org/10.1086/651262.CrossRefPubMed

61.

Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. AntimicrobAgents Chemother. 2008;52(2):735–8.CrossRef

62.

Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One. 2013;8(3):e60431. https://doi.org/10.1371/journal.pone.0060431.CrossRefPubMedPubMedCentral

63.

Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. ClinInfectDis. 2008;46(2):e12–e8.

64.

Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis. 2007;195(5):756–64. https://doi.org/10.1086/511438.CrossRefPubMedPubMedCentral

65.

Baddley JW, Forrest GN, Practice ASTIDCo. Cryptococcosis in solid organ transplantation-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33(9):e13543. https://doi.org/10.1111/ctr.13543.CrossRef

66.

Cruz MC, Del Poeta M, Wang P, Wenger R, Zenke G, Quesniaux VF, et al. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother. 2000;44(1):143–9. https://doi.org/10.1128/aac.44.1.143-149.2000.CrossRefPubMedPubMedCentral

67.

Silveira FP, Husain S, Kwak EJ, Linden PK, Marcos A, Shapiro R, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis. 2007;9(1):22–7. https://doi.org/10.1111/j.1399-3062.2006.00149.x.CrossRefPubMed

68.

Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation. 2006;81(1):17–20. https://doi.org/10.1097/01.tp.0000189713.14993.db.CrossRefPubMed

69.

Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007;44(2):204–12. https://doi.org/10.1086/510388.CrossRefPubMed

70.

Chang FY, Singh N, Gayowski T, Wagener MM, Mietzner SM, Stout JE, et al. Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin. Transplantation. 2000;69(1):70–5. https://doi.org/10.1097/00007890-200001150-00014.CrossRefPubMed

71.

Carvalho Neiva Tde J, dos Santos JI. Effect of pathogenic yeasts on human platelet aggregation. Braz J Infect Dis. 2003;7(6):370–4. https://doi.org/10.1590/s1413-86702003000600003.CrossRefPubMed

72.

Singh N, Lortholary O, Dromer F, Alexander BD, Gupta KL, John GT, et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings. Transplantation. 2008;86(5):647–51.CrossRef

73.

Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoSMed. 2007;4(2):e21.

74.

Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. ClinInfectDis. 2009;48(11):1566–76.

75.

Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. ClinInfectDis. 2010;51(9):1062–9.

76.

Hakyemez IN, Erdem H, Beraud G, Lurdes M, Silva-Pinto A, Alexandru C, et al. Prediction of unfavorable outcomes in cryptococcal meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study. Eur J Clin Microbiol Infect Dis. 2018;37(7):1231–40. https://doi.org/10.1007/s10096-017-3142-1.CrossRefPubMed

77.

Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. EmergInfectDis. 2001;7(3):375–81.

78.

Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis. 2011;52(4):e94–8. https://doi.org/10.1093/cid/ciq216.CrossRefPubMed

79.

•• Camargo JF, Simkins J, Schain DC, Gonzalez AA, Alcaide ML, Anjan S, et al. A cluster of donor-derived Cryptococcus neoformans infection affecting lung, liver, and kidney transplant recipients: case report and review of literature. Transpl Infect Dis. 2018;20(2):e12836. https://doi.org/10.1111/tid.12836Report showing delay of donor-derived cryptococcal infection up to 3 months post-transplant, when it is typically thought to occur within 30 days of transplant. CrossRefPubMed

80.

Vidal JE, Boulware DR. Lateral flow assay for cryptococcal antigen: an important advance to improve the continuum of Hiv care and reduce cryptococcal meningitis-related mortality. Rev Inst Med Trop Sao Paulo. 2015;57(Suppl 19):38–45. https://doi.org/10.1590/S0036-46652015000700008.CrossRefPubMedPubMedCentral

81.

Forrest GN, Bhalla P, DeBess EE, Winthrop KL, Lockhart SR, Mohammadi J, et al. Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases. Transpl Infect Dis. 2015;17(3):467–76. https://doi.org/10.1111/tid.12370.CrossRefPubMed

82.

Vijayan T, Chiller T, Klausner JD. Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med Lab Obs. 2013;45(3):16 8, 20.PubMedPubMedCentral

83.

Dubbels M, Granger D, Theel ES. Low cryptococcus antigen titers as determined by lateral flow assay should be interpreted cautiously in patients without prior diagnosis of cryptococcal infection. J Clin Microbiol. 2017;55(8):2472–9. https://doi.org/10.1128/JCM.00751-17.CrossRefPubMedPubMedCentral

84.

Lee GH, Arthur I, Leung M. False-negative serum cryptococcal lateral flow assay result due to the prozone phenomenon. J Clin Microbiol. 2018;56(4):e01878–17. https://doi.org/10.1128/JCM.01878-17.CrossRefPubMedPubMedCentral

85.

Liesman RM, Strasburg AP, Heitman AK, Theel ES, Patel R, Binnicker MJ. Evaluation of a commercial multiplex molecular panel for diagnosis of infectious meningitis and encephalitis. J Clin Microbiol. 2018;56(4):e01927–17. https://doi.org/10.1128/JCM.01927-17.CrossRefPubMedPubMedCentral

86.

Van TT, Kim TH, Butler-Wu SM. Evaluation of the Biofire FilmArray meningitis/encephalitis assay for the detection of Cryptococcus neoformans/gattii. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.01.007.

87.

Rhein J, Boulware DR, Bahr NC. 1,3-beta-D-glucan in cryptococcal meningitis. Lancet Infect Dis. 2015;15(10):1136–7. https://doi.org/10.1016/S1473-3099(15)00306-0.CrossRefPubMed

88.

Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. In: Principles and practice of infectious diseases. 9th ed. Philadelphia: Elsevier; 2019.

89.

Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis. 2009;49(11):1721–8. https://doi.org/10.1086/647948.CrossRefPubMedPubMedCentral

90.

Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. NEnglJ Med. 2013;368(14):1291–302.CrossRef

91.

Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoSONE. 2008;3(8):e2870.CrossRef

92.

Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374(6):542–54. https://doi.org/10.1056/NEJMoa1509024.CrossRefPubMedPubMedCentral

93.

Panackal AA, Marr KA, Williamson PR. Dexamethasone in cryptococcal meningitis. N Engl J Med. 2016;375(2):188–90. https://doi.org/10.1056/NEJMc1605205.CrossRefPubMedPubMedCentral

94.

Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 2019;19(8):843–51. https://doi.org/10.1016/S1473-3099(19)30127-6.CrossRefPubMedPubMedCentral

95.

Smilnak GJ, Charalambous LT, Cutshaw D, Premji AM, Giamberardino CD, Ballard CG, et al. Novel treatment of cryptococcal meningitis via neurapheresis therapy. J Infect Dis. 2018;218(7):1147–54. https://doi.org/10.1093/infdis/jiy286.CrossRefPubMedPubMedCentral

Titel: Cryptococcosis in Liver Transplant Candidates and Recipients
verfasst von: Sara Gore
Graeme N. Forrest
Publikationsdatum: 20.06.2020
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 3/2020
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-020-00399-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Cryptococcosis in Liver Transplant Candidates and Recipients

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Candida Onychomycosis: an Old Problem in Modern Times

Innovative Approaches for Histoplasma Detection

Antifungal Penetration and Distribution into Organs and Tissue

Review of the Current Management of Urinary Tract Infections due to Fluconazole-Resistant and Non-Albicans Candida Species

Conidiobolomycosis in Pediatric Patients

Emerging Fungal Cutaneous Infections in Immunocompromised Patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin